Zobrazeno 1 - 10
of 603
pro vyhledávání: '"Klouvas, G"'
Autor:
Pentheroudakis, G. a, Kostadima, L. a, Fountzilas, G. b, Kalogera-Fountzila, A. c, Klouvas, G. d, Kalofonos, C. e, Pavlidis, N. a, ∗
Publikováno v:
In Lung Cancer 2004 45(3):349-355
Publikováno v:
Forum of Clinical Oncology, Vol 6, Iss 1, Pp 18-26 (2015)
Background: Novel therapeutic approaches and new compounds during the last decade have prolonged survival of breast cancer patients with metastatic disease, resulting in higher incidence of central nervous system (CNS) metastases. Many of these patie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7539dc67ca0eae339ca05b86c4c97f7a
https://doi.org/10.1515/fco-2015-0004
https://doi.org/10.1515/fco-2015-0004
Autor:
Vigdorovits, Alon1 (AUTHOR) alonvigdorovits@gmail.com, Olteanu, Gheorghe-Emilian2,3 (AUTHOR) emilian.olteanu@bccancer.bc.ca, Pascalau, Andrei-Vasile1 (AUTHOR) pascalau.andrei@gmail.com, Pirlog, Radu4,5,6 (AUTHOR) ioananeagoe29@gmail.com, Berindan-Neagoe, Ioana6,7 (AUTHOR), Pop, Ovidiu-Laurean1 (AUTHOR) drovipop@yahoo.com
Publikováno v:
Diagnostics (2075-4418). Dec2024, Vol. 14 Issue 23, p2660. 11p.
Autor:
Fountzilas, George, Polichronis, A., Katsohis, C., Gennatas, Constantinos, Toussis, D., Skarlos, Dimosthenis V., Kosmidis, Paraskevas A., Vassilaros, S., Semoglou, C., Giannakakis, T., Fahantidis, E., Klouvas, G. D., Tsavaris, N., Konstantaras, C., Makrantonakis, P., Kolotas, C., Zamboglou, N., Tsiliakos, S., Hainoglou, D., Mylonakis, N., Pavlidis, Nicholas
Publikováno v:
Oncology (Switzerland)
362 evaluable node-positive patients with stage II breast cancer were randomized, receiving either 6 cycles of conventional CMF or 6 cycles of the combination of cyclophosphamide (500 mg/m2), mitoxantrone (Novantrone 10 mg/ m2), and fluorouracil (500
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c5026e11795c025b7d80d87ee6dc2ed2
https://doi.org/10.1159/000227550
https://doi.org/10.1159/000227550
Background: The HER2 gene has been established as a valid biological marker for the treatment of breast cancer patients with trastuzumab and probably other agents, such as paclitaxel and anthracyclines. The TOP2A gene has been associated with respons
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::24ddb2fb5e80a59c6d81de33172df082
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3087993
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3087993
We present a case of interstitial nephritis and nephrogenic diabetes insipidus (NDI) in a patient treated with pemetrexed (500 mgm2) for non-small cell lung cancer. Renal impairment and diabetes insipidus appeared after the first treatment cycle whil
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::32e922a005c161f9b2bd9f1f2807ccee
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3111942
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3111942
Autor:
Kalef-Ezra, J. A., Glaros, D., Klouvas, G. D., Hatzikonstantinou, I., Karantanas, A. H., Siamopoulos, K. C., Pavlidis, Nicholas
Publikováno v:
British Journal of Radiology
The possibility of increased risk for osteoporosis in breast cancer patients treated with tamoxifen was investigated. 26 patients aged 41-65 years without skeletal metastases were studied. All patients were treated with 20 mg/d tamoxifen for a mean t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b16533647b06738bc2f951835f403b76
https://doi.org/10.1259/0007-1285-65-773-417
https://doi.org/10.1259/0007-1285-65-773-417
It is controversial whether non-small cell lung cancer (NSCLC) in the elderly constitutes a distinct clinico-biological entity compared to younger counterparts. As reported data are scant and discordant, we sought to analyze retrospectively the medic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::002d04c8982601540aa5505fdb3f8fa5
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3062198
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3062198
Publikováno v:
Lung Cancer
In a pilot phase II study we have treated 25 patients with small cell lung cancer by utilizing 3 non-cross resistant drug regimens given in a sequential fashion in combination with radiotherapy to the primary tumor. VAC regimen (etoposide, doxorubici
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e20a98a12a245c7a301e5461616c3151
https://doi.org/10.1016/0169-5002(91)90023-y
https://doi.org/10.1016/0169-5002(91)90023-y